Fibrinogen consumption. Representative nonreduced immunoblot (5%-15%) of fibrinogen from consecutive 60-second bleeding-time blood samples for a stable CAD patient and a patient with AMI. Fibrinogen concentrations were determined by densitometry of immunoblots as described in “Fibrinogen consumption.” Data for all CAD patients (n = 28, ▵) and AMI patients (n = 28, ▴) are plotted as the means plus or minus SEM.